Why Did The NeuroSense (NRSN) Stock Rise By 12% In Extended Trading?

Following the release of a business update, NeuroSense Therapeutics Ltd. (NASD: NRSN) increased 12.58% to $1.70 in after-hours trading on Thursday.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

What kind of upgrade has NRSN offered?

This month, NeuroSense (NRSN) released a business update for the three months that concluded on September 30, 2022.

Enrollments of patients in the US and Italy

The clinical development strategy for PrimeC, which is presently being assessed in PARADIGM, a double-blind, placebo-controlled, multi-center Phase 2b clinical study, saw NeuroSense reach numerous objectives during the third quarter. More than 40% of the patients required to finish the experiment have already signed up.

The company’s investigational new drug (IND) has been approved by the Food and Drug Administration (FDA) (IND). Additionally, NRSN obtained endorsement from the Italian Medicines Agency (AIFA). NRSN is anticipated to start for PARADIGM in the U.S. and Europe in the next weeks after the acceptance of both of these patent enrollment applications.

PK Studies with Multiple Doses

Results from a multi-dose pharmacokinetic (PK) research were made public by NRSN in Q3 (NCT05436678). The PK open-label, randomized, multi-dose, three-treatment, three-period crossover study assessed the impact of food on PrimeC’s bioavailability in adult subjects in the U.S. under an FDA-cleared IND protocol in comparison to the bioavailability of co-administered ciprofloxacin tablets and celecoxib capsules.

Based on the findings, NRSN believes PrimeC’s PK profile supports the formulation’s extended-release features since the active ingredients’ concentrations have been synchronized in an effort to possibly optimize their synergistic effects.

Conferences and publications

Results from NeuroSense’s Phase 2a study were presented in an article co-authored by the scientific team at NeuroSense and top ALS researchers, titled “Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS,” which was printed in the peer-reviewed journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.

More from the NRSN

Through ALS conferences held during and after the conclusion of Q3, NeuroSense (NRSN) enhanced current relationships and investigated potential research collaborations. The TRICALS Consortium 2022 Masterclass, the largest European research initiative to find a cure for ALS, was held in the Netherlands and featured presentations on the use of biomarkers in ALS clinical trials by NRSN’s Chief Medical Officer, Ferenc Tracik, MD, and Head of Scientific Program, Shiran Zimri, Ph.D.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular